The fraction of activated N-methyl-D-Aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole

Journal of Neural Transmission

Volumn 115, Issue 8, 2008, Pages 1119-1126

  Rammes, G ^a,b   Zieglgansberger W ^a   Parsons, C G ^c  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

ALS; Amyotrophic lateral sclerosis; EPSC; Hippocampus; Memantine; NMDA receptor; Riluzole

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMATE RELEASE INHIBITOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RILUZOLE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE SEVERITY; DRUG MECHANISM; EXCITOTOXICITY; HIPPOCAMPUS; IN VITRO STUDY; MALE; MOUSE; NERVE EXCITABILITY; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SYNAPTIC TRANSMISSION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUTAMIC ACID; HIPPOCAMPUS; MALE; MICE; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; RECEPTORS, N-METHYL-D-ASPARTATE; RILUZOLE; SYNAPTIC TRANSMISSION;

EID: 49849103349     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-008-0059-y     Document Type: Article

References (56)

1. M Arundine M Tymianski 2003 Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity Cell Calcium 34 325 337
2. RD Azbill X Mu JE Springer 2000 Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes Brain Res 871 175 180
3. MF Beal 1995 Aging, energy, and oxidative stress in neurodegenerative diseases Ann Neurol 38 357 366
4. E Benoit D Escande 1991 Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre Pflugers Arch 419 603 609
5. G Bensimon L Lacomblez V Meininger 1994 A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group N Engl J Med 330 585 591
6. MG Blanton JJ Lo Turco AR Kriegstein 1989 Whole cell recording from neurons in slices of reptilian and mammalian cerebral cortex J Neurosci Methods 30 203 210
7. N Burnashev H Monyer PH Seeburg B Sakmann 1992 Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit Neuron 8 189 198
8. HS Chen SA Lipton 1997 Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism J Physiol (Lond) 499 Pt 1 27 46
9. HSV Chen JW Pellegrini SK Aggarwal SZ Lei S Warach FE Jensen SA Lipton 1992 Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine-therapeutic advantage against NMDA receptor-mediated neurotoxicity J Neurosci 12 4427 4436
10. A Cheramy L Barbeito G Godeheu J Glowinski 1992 Riluzole inhibits the release of glutamate in the caudate nucleus of the cat invivo Neurosci Lett 147 209 212
11. KA Clark GL Collingridge 1995 Synaptic potentiation of dual-component excitatory postsynaptic currents in the rat hippocampus J Physiol 482 Pt 1 39 52
12. W Danysz CG Parsons 2002 Neuroprotective potential of ionotropic glutamate receptor antagonists Neurotox Res 4 119 126
13. W Danysz CG Parsons 2003 The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease preclinical evidence Int J Geriatric Psychiatry 18 S23 S32
14. HC Diener 1998 Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group Cerebrovasc Dis 8 172 181
15. A Doble 1996 The pharmacology and mechanism of action of riluzole Neurology 47 S233 S241
16. F Duprat F Lesage AJ Patel M Fink G Romey M Lazdunski 2000 The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK Mol Pharmacol 57 906 912
17. ME Frizzo LP Dall'Onder KB Dalcin DO Souza 2004 Riluzole enhances glutamate uptake in rat astrocyte cultures Cell Mol Neurobiol 24 123 128
18. EF Goodall KE Morrison 2006 Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment Expert Rev Mol Med 8 1 22
19. PH Gordon 2005 Advances in clinical trials for amyotrophic lateral sclerosis Curr Neurol Neurosci Rep 5 48 54
20. S Hestrin 1992 Activation and desensitization of glutamate-activated channels mediating fast excitatory synaptic currents in the visual cortex Neuron 9 991 999
21. CS Huang JH Song K Nagata JZ Yeh T Narahashi 1997 Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons J Pharmacol Exp Ther 282 1280 1290
22. C Krieger RA Lanius SL Pelech CA Shaw 1996 Amyotrophic lateral sclerosis: the involvement of intracellular Ca(2+) and protein kinase C Trends Pharmacol Sci 17 114 120
23. L Lacomblez G Bensimon PN Leigh P Guillet V Meininger 1996 Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/Riluzole Study Group II Lancet 347 1425 1431
24. W Löscher C Rundfeldt D Honack 1993 Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy Eur J Neurosci 5 1545 1550
25. MB MacIver SM Amagasu AA Mikulec FA Monroe 1996 Riluzole anesthesia: use-dependent block of presynaptic glutamate fibers Anesthesiology 85 626 634
26. J Mantz 1996 Riluzole CNS Drug Rev 2 40 51
27. J Mantz V Laudenbach JB Lecharny D Henzel JM Desmonts 1994 Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes Eur J Pharmacol 257 R7 R8
28. D Martin MA Thompson JV Nadler 1993 The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area ca1 Eur J Pharmacol 250 473 476
29. EG McGeer PL McGeer 2005 Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis BioDrugs 19 31 37
30. JJ Miguel-Hidalgo XA Alvarez R Cacabelos G Quack 2002 Neuroprotection by memantine against neurodegeneration induced by beta- amyloid(1-40) Brain Res 958 210 221
31. Miller RG, Mitchell JD, Lyon M, Moore DH (2007) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev CD001447
32. KW Muir KR Lees SJ Hamilton CF George SF Hobbiger MW Lunnon 1995 A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke Ann N Y Acad Sci 765 328 329
33. Parsons CG, Danysz W (2002) ALS. In: Lodge D, Danysz W, Parsons CG (eds) Therapeutic potential of ionotropic glutamate receptor antagonists and modulators. F•P. Graham Publishing Co, New York, pp 540-562
34. CG Parsons W Danysz G Quack 1998 Glutamate in CNS Disorders as a target for drug development: an update Drug News Perspect 11 523 569
35. CG Parsons W Danysz G Quack 1999 Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data Neuropharmacology 38 735 767
36. CG Parsons R Gruner J Rozental J Millar D Lodge 1993 Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3, 5-dimethyladamantan) Neuropharmacology 32 1337 1350
37. CG Parsons A Stoffler W Danysz 2007 Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse Neuropharmacology 53 699 723
38. A Plaitakis CO Fesdjian P Shashidharan 1996 Glutamate antagonists in amyotrophic lateral sclerosis: a review of their therapeutic potential CNS Drugs 5 437 456
39. M Prakriya S Mennerick 2000 Selective depression of low-release probability excitatory synapses by sodium channel blockers Neuron 26 671 682
40. G Rammes W Danysz CG Parsons 2008 Pharmacodynamics of memantine: an update Curr Neuropharmacol 6 55 78
41. MA Rogawski 2006 Diverse mechanisms of antiepileptic drugs in the development pipeline Epilepsy Res 69 273 294
42. JD Rothstein 1995 Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis Clin Neurosci 3 348 359
43. PJ Shaw PG Ince 1997 Glutamate, excitotoxicity and amyotrophic lateral sclerosis J Neurol 244 S3 S14
44. RA Silver D Colquhoun SG Cullcandy B Edmonds 1996 Deactivation and desensitization of non-NMDA receptors in patches and the time course of EPSCs in rat cerebellar granule cells Deactivation and desensitization of non-NMDA receptors in patches and the time course of EPSCs in rat cerebellar granule cells J Physiol Lond 496 891
45. JH Song CS Huang K Nagata JZ Yeh T Narahashi 1997 Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels J Pharmacol Exp Ther 282 707 714
46. A Stefani F Spadoni G Bernardi 1997 Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies Exp Neurol 147 115 122
47. BJ Traynor L Bruijn R Conwit F Beal G O'Neill SC Fagan ME Cudkowicz 2006 Neuroprotective agents for clinical trials in ALS: a systematic assessment Neurology 67 20 27
48. M Umemiya AJ Berger 1995 Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones Br J Pharmacol 116 3227 3230
49. P Van Damme M Dewil W Robberecht L Van Den Bosch 2005 Excitotoxicity and amyotrophic lateral sclerosis Neurodegener Dis 2 147 159
50. L Van Den Bosch P Van Damme E Bogaert W Robberecht 2006 The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis Biochim Biophys Acta 1762 1068 1082
51. R Wang D Zhang 2005 Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model Eur J Neurosci 22 2376 2380
52. MD Weiss P Weydt GT Carter 2004 Current pharmacological management of amyotrophic Expert Opin Pharmacother 5 735 746
53. GL Wenk W Zajaczkowski W Danysz 1997 Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B Behav Brain Res 83 129 133
54. GL Wenk CG Parsons W Danysz 2006 Potential role of N-methyl-d-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine Behav Pharmacol 17 411 424
55. H Yokoo S Shiraishi H Kobayashi T Yanagita R Yamamoto A Wada 1998 Selective inhibition by riluzole of voltage-dependent sodium channels and catecholamine secretion in adrenal chromaffin cells Naunyn-Schmied Arch Pharmacol 357 526 531
56. F Zipp H Baas PA Fischer 1993 Lamotrigine-antiparkinsonian activity by blockade of glutamate release J Neural Transm Parkinsons 5 67 75